echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first IL-25 monoclonal antibody!

    The first IL-25 monoclonal antibody!

    • Last Update: 2022-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    On November 15, the CDE official website showed that Xinkanghe’s XKH001 injection clinical trial application was approved by the Food and Drug Administration for the treatment of moderate to severe asthma


    XKH001 is the first IL-25 monoclonal antibody independently developed by Xinkanghe with global intellectual property rights


    XKH001 can specifically neutralize human IL-25, block its binding to the receptor, and thereby inhibit the inflammatory response caused by Th2


    It is worth noting that in July 2021, Xinkanghe announced that XKH001 was approved by the FDA for phase I clinical trials, becoming the world's first FDA-approved clinical IL-25 inhibitor


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.